Abstract:Common chemotherapy is unable to eliminate the heterogeneous side population of cancer cells (such as cancer stem-like cells),resulting in poor prognosis.The heterogeneity of cancer cells causes an extensive multidrug resistance through the aberrantly active Hedgehog (Hh) signaling pathway.Cyclopamine is a chemical compound that can block Hh signaling pathway,and a combination use of cyclopamine with anticancer drug would be beneficial for killing heterogeneous cancer cells.In the present study,we aimed to develop a kind type of functional drug liposomes for eliminating heterogeneous cancer.The study was performed on human breast cancer cells.A distearoylphosphoethanolamine polyethylene glycol (DSPE-PEG2000)-cyclopamine conjugate was newly synthesized by a nucleophilic substitution reaction,and confirmed by MALDI-TOF mass.An HPLC method was established and validated for qualification of epirubicin.Functional epirubicin liposomes were successful constructed by modifying with DSPE-PEG2000-cyclopamine,displaying a particle size in nano-scale (approximately 98 nm) and a high epirubicin encapsulation (＞97％).The CD44+/CD24-side population was characterized in defining heterogeneous breast cancer cells.As compared with regular epirubicin liposomes,functional epirubicin liposomes exhibited an evidently enhanced cellular drug uptake and a significant killing effect in overall breast cancer cells.In conclusion,the functional epirubicin liposomes could be a useful drug delivery carrier for eliminating heterogeneous breast cancer cells.

A novel type of functional epirubicin liposomes modified with DSPE-PEG2000-cyclopamine conjugate for eliminating heterogeneous breast cancer cells